ATEC Leads EPS Revision Screener Winners, Jumps 18.7% to $10.66
Alphatec Holdings (ATEC) jumped 18.7% to $10.66 after an 86.6% next-year EPS growth estimate surfaced, the strongest of five stocks flagged by our EPS revision screener since September 9. Fossil Group gained 12.2% following a massive 664.7 percentage-point upward revision to 776.2%, while Navan added 10.7% on raised guidance.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| ATEC | Healthcare | 2026-09-09 | N/A | +18.7% |
| FOSL | Consumer Cyclical | 2026-09-10 | +664.7pp | +12.2% |
| NAVN | Technology | 2026-09-10 | N/A | +10.7% |
| TWST | Healthcare | 2026-09-09 | +1.5pp | +10.0% |
| EVI | Industrials | 2026-09-10 | N/A | +9.1% |
Why did ATEC stock jump in September 2026?
ATEC jumped 18.7% to $10.66 after our EPS revision screener detected an 86.6% next-year EPS growth estimate on September 9, 2026.
The medical device maker saw no company-specific earnings news during the window, suggesting the sharp upward revision in forward growth expectations alone attracted buyers. In the healthcare sector, where Alphatec competes in spine surgery technology, backlog and procedure volume trends have been recovering. The price gain reflects early confirmation that the elevated EPS growth estimate is being validated by the market.
ATEC EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: ATEC
Why did ATEC stock jump in September 2026?
ATEC jumped 18.7% from $8.98 to $10.66 after an 86.6% next-year EPS growth estimate was flagged by our revision screener on September 9, 2026.
Is ATEC a buy after the rally?
The 18.7% move reflects the market validating an 86.6% EPS growth estimate, but with no company-specific earnings news in the window, investors should watch for confirmation from procedure volume and backlog data.
What is ATEC's EPS growth estimate?
Alphatec Holdings has a current next-year EPS growth estimate of 86.6%, which triggered the screener detection on September 9, 2026.
Why did FOSL stock jump in September 2026?
FOSL jumped 12.2% to $5.04 after its next-year EPS growth estimate was revised from 111.5% to 776.2%, a 664.7 percentage-point increase, on September 10, 2026.
The dramatic upward revision reflects an extraordinary swing in forward earnings expectations for the watch and accessories maker. No company-specific earnings news surfaced during the window, so the move appears driven purely by the magnitude of the estimate revision. The 664.7 percentage-point revision is by far the largest in this cohort, suggesting analysts are modeling a dramatic earnings inflection.
FOSL EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: FOSL
Why did FOSL stock surge in September 2026?
FOSL surged 12.2% to $5.04 after its next-year EPS growth estimate was revised upward from 111.5% to 776.2%, a 664.7 percentage-point increase, on September 10, 2026.
What caused FOSL's EPS estimate revision?
The next-year EPS growth estimate for Fossil Group was revised from 111.5% to 776.2%, a 664.7 percentage-point increase that triggered our screener, though no company-specific earnings news was found in the window.
Is FOSL a buy after the rally?
The 12.2% gain to $5.04 reflects the market pricing in a dramatic earnings inflection, but the absence of confirming news means investors should verify what drove the 664.7 percentage-point revision.
Why did TWST stock jump in September 2026?
TWST jumped 10.0% to $138.10 after our EPS revision screener detected a modest but meaningful upward revision in next-year EPS growth from 35.1% to 36.6% on September 9, 2026.
The synthetic biology company saw no company-specific earnings news during the window, so the move likely reflects broader sector strength in life sciences tools and growing confidence in its DNA synthesis platform. The 1.5 percentage-point revision is small in absolute terms but significant for a company already modeling 35%+ growth. The $138.10 price level marks a notable recovery for the stock.
TWST EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: TWST
Why did TWST stock jump in September 2026?
TWST jumped 10.0% from $125.52 to $138.10 after its next-year EPS growth estimate was revised upward from 35.1% to 36.6% on September 9, 2026, with no company-specific earnings news driving the move.
What caused TWST's surge?
The 10.0% gain followed a 1.5 percentage-point upward revision in Twist Bioscience's next-year EPS growth estimate, from 35.1% to 36.6%, signaling incremental analyst confidence.
What is TWST's EPS growth estimate?
Twist Bioscience's next-year EPS growth estimate was revised from 35.1% to 36.6% on September 9, 2026, which triggered our screener.
Why did EVI stock jump in September 2026?
EVI gained 9.1% to $16.86 after our EPS revision screener detected a 29.9% next-year EPS growth estimate on September 10, 2026.
The industrial equipment distributor saw no company-specific earnings news during the window, indicating the move was driven by the positive growth estimate and broader industrial sector momentum. EVI Industries has been consolidating the highly fragmented commercial laundry distribution market, and the 29.9% growth estimate suggests analysts see continued accretion from its acquisition strategy. The price move to $16.86 represents a steady climb from the $15.45 detection level.
EVI EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: EVI
Why did EVI stock jump in September 2026?
EVI gained 9.1% from $15.45 to $16.86 after our screener detected a 29.9% next-year EPS growth estimate on September 10, 2026.
What caused EVI's surge?
The 9.1% move followed the detection of a 29.9% next-year EPS growth estimate, with no company-specific earnings news in the window, suggesting sector momentum and acquisition-driven growth expectations.
Is EVI a buy after the rally?
EVI's 29.9% EPS growth estimate and its commercial laundry distribution roll-up strategy support the 9.1% gain, though the absence of news means investors should watch for acquisition announcements.
Today's screener winners — led by ATEC's 18.7% jump and FOSL's 664.7 percentage-point EPS revision — show that forward earnings estimate changes remain a powerful catalyst even without company-specific news. NAVN stands out as the only name with confirming earnings news, raising guidance to 32% growth, which validates the broader pattern of estimate-driven rallies across healthcare and consumer cyclicals.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →